Home Page ελληνικά|
Company  |  News - Publications  |  Offices  |  Conferences  |  Events  |  Newsletter  |  Career  |  Register
 
Services
Credit Risk Services
Marketing and Sales Solutions
Management Consultants
People and Employment Solutions
Contact Center
Receivables Management
PHARMACEUTICAL COMPANIES
Print    Send Email
 
CATEGORY: OTHER SECTORS
EDITION: 8
DATE: November, 2017
COUNTRY: Greece
 
   
LANGUAGES:  Greek Available Price 670,00 € Buy Now!
  English Not Available
  Bulgarian Not Available
  Romanian Not Available
  Serbian Not Available
Summary

1. Introduction - General Information
1.1 Overview of Economic Developments
1.2 Introduction
1.3 General Information
1.4 Institutional Framework
1.5 Distribution Network of Pharmaceutical Products
1.6 Important Industry Bodies
 -The National Organization for Medicines (EOF)
 -The Institute of Pharmaceutical Research & Technology (IFET)
 -The Hellenic Association of Pharmaceutical Companies (SFEE)
 -Panhellenic Union of Pharmaceutical Industry (P.E.F.)
Appendix to Chapter 1

2. The Demand for Pharmaceutical Products
2.1 Factors that Shape Demand
2.2 Pharmaceutical and Health Expenditure
2.3 The Infrastructure of the Health System in Greece
2.4 Producer and Consumer Price Index for Pharmaceutical Products
Appendix to Chapter 2

3. The Supply of the Sector
3.1 Structure and Breakdown of the Sector
3.2 Advertising Expenditure of Pharmaceutical Companies and Products
3.3 Presentation of Pharmaceutical Manufacturers
3.4 Total Turover of Pharmaceutical Manufacturers
3.5 Financial Analysis of Pharmaceutical Manufacturers
-Profitability
-Performance
-Liquidity
-Financial Structure
-Activity
-Consolidated Balance Sheet Analysis
3.6 Comparison of the Financial Ratios of Manufacturers with the Sector - Benchmarking - Benchmarking
3.7 Overall Ranking of Pharmaceutical Manufacturers based on Profitability
3.8 Presentation of Pharmaceutical Importers
3.9 Total Turover of Pharmaceutical Importers
3.10 Financial Analysis of Pharmaceutical Importers
-Profitability
-Performance
-Liquidity
-Financial Structure
-Activity
-Consolidated Balance Sheet Analysis
Comparison of the Financial Ratios of Pharmaceutical Importers with the Sector - Benchmarking
3.12 The Sector's Creditworthiness Over Time
3.12.1 Creditworthiness of Assessed Businesses
3.12.2 Creditworthiness of the Pharmaceuticals-Cosmetics-Detergents Manufacturing and Commercial Sector)
3.13 The Sector's Trading Conduct Over Time
3.13.1 Trading Conduct of Assessed Businesses
3.13.2 Trading Conduct in the Wider Sector of Pharmaceutical Companies
Appendix to Chapter 3

4. The Market of Pharmaceutical Companies
4.1 Domestic Production of Medicines
4.2 Imports - Exports of Pharmaceutical Products Over Time
4.2.1 Analysis of Imports per Product Group - Principal Countries of Origin
4.2.2 Analysis of Exports per Product Group - Principal Countries of Destination
4.2.3 Index of Competitiveness for Medicines - Trade Balance
4.3 Market Size of Pharmaceutical Companies
 -Hospital / EOPYY (National Organization for the Provision of Healthcare Services) to Pharmaceutical Companies
Appendix to Chapter 4

5. The Pharmaceutical Industry in the International & European Market
5.1 The Global and European Pharmaceutical Market
5.2 Key Data on the Health Industry in OECD Member States
Appendix to Chapter 5

6. Conclusions and Prospects
6.1 Latest Business News in the Sector of Pharmaceutical Companies
6.2 Analysis of Competitive Environment - SWOT Analysis
 -General
 -Threat of New Entrants
 -Threat of Substitute Products
 -Bargaining Power of Suppliers
 -Bargaining Power of Customers
 -Competitive Rivalry within the Industry
 -SWOT Analysis
Appendix I: Memorandum of Understanding on Specific Economic Policy Conditionality (Health Sector)
 -Modernization of the healthcare system
 -Monitoring of pharmaceutical expenditure
 -Emergency measures for achieving the general objectives
 -Medicines pricing
 -Prescribing and monitoring
 -Increase in the use of generic medicines
 -Review of medical services by suppliers affiliated with EOPYY
Appendix II: Balance Sheets of Sector Companies
Appendix III: List of Sector Studies carried out by the Department of Economic Research, ICAP Group

 -Benchmarking of pharmaceutical manufacturers
 -Benchmarking of pharmaceutical importers

TABLES

App1.1 Pharmaceutical legislation in force (January 2000-September 2013)
Table 2.1 Age groups of over 65 year-olds as a share (%) in the country's total population
Table 2.2 Pharmaceutical and Health Expenditure (2005-2012)
Table 2.3 Producer Price Index in the Manufacturing Industry (2001-2012)
Table 2.4 Consumer Price Index for Medicines (2001-2012)
App2.1 Estimated population in Greece per sex and age group (2010-2012)
App2.2 Population projections of Greece by age (2020-2050)
App2.3 Total current health expenditure (2009-2011)
App2.4 Government bodies' financing to suppliers of health products and services (2009-2011)
App2.5 Average monthly health and pharmaceutical expenditure by classes of total monthly value of purchases (2010)
App2.6 Average monthly household expenditure on health, by region (2010)
Table 3.1 Presentation of pharmaceutical manufacturers
Table 3.2 Total Turnover pharmaceutical manufacturers (2008-2012)
Table 3.3 Profitability ratios of pharmaceutical manufacturers (2008 - 2012)
Table 3.4 Performance ratios of pharmaceutical manufacturers (2008 - 2012)
Table 3.5 Liquidity ratios of pharmaceutical manufacturers (2008 - 2012)
Table 3.6 Financial structure ratios of pharmaceutical manufacturers (2008 - 2012)
Table 3.7 Activity ratios of pharmaceutical manufacturers (2008 - 2012)
Table 3.8 Sources and uses of new funds of pharmaceutical manufacturers (2012)
Table 3.9 Consolidated balance sheet of pharmaceutical manufacturers
(2011-2012)
Table 3.10 Consolidated balance sheet of profitable pharmaceutical manufacturers (2011-2012)
Table 3.11 Consolidated balance sheet of loss-making pharmaceutical manufacturers (2011-2012)
Table 3.12 Financial ratios of BOEHRINGER INGELHEIM ELLAS A.E. and comparison with the sector (2010-2012)
Table 3.13 Financial ratios of VIANEX S.A. and comparison with the sector (2010-2012)
Table 3.14 Financial ratios of PHARMATHEN S.A. and comparison with the sector (2010-2012)
Table 3.15 Financial ratios of ELPEN PHARMACEUTICAL CO. INC. S.A. and comparison with the sector (2010-2012)
Table 3.16 Financial ratios of DEMO S.A. PHARMACEUTICAL INDUSTRY and comparison with the sector (2010-2012)
Table 3.17 Financial ratios of SPECIFAR S.A. and comparison with the sector (2009-2011)
Table 3.18 Ranking of pharmaceutical manufacturers based on gross profits (2011-2012)
Table 3.19 Ranking of pharmaceutical manufacturers based on profit before income tax (2011-2012)
Table 3.20 Ranking of pharmaceutical manufacturers based on EBITDA profits (2011-2012)
Table 3.21 Presentation of Pharmaceutical Importers
Table 3.22 Total turnover of pharmaceutical importers (2008-2012)
Table 3.23 Profitability ratios of pharmaceutical importers (2008 - 2012)
Table 3.24 Performance ratios of pharmaceutical importers (2008 - 2012)
Table 3.25 Liquidity ratios of pharmaceutical importers (2008 - 2012)
Table 3.26 Financial structure ratios of pharmaceutical importers (2008 - 2012)
Table 3.27 Activity ratios of pharmaceutical importers (2008 - 2012) 1
Table 3.28 Sources and uses of new funds of pharmaceutical importers (2012)
Table 3.29 Consolidated balance sheet of pharmaceutical importers (2011-2012)
Table 3.30 Consolidated balance sheet of profitable pharmaceutical importers (2011-2012)
Table 3.31 Consolidated balance sheet of loss-making pharmaceutical importers (2011-2012)
Table 3.32 Financial ratios of NOVARTIS (HELLAS) S.A.C.I. and comparison with the sector (2010-2012)
Table 3.33 Financial ratios of PFIZER HELLAS S.A. and comparison with the sector (2010-2012) 1
Table 3.34 Financial ratios of SANOFI - AVENTIS S.A. and comparison with the sector (2010-2012)
Table 3.35 Financial ratios of GLAXOSMITHKLINE S.A. and comparison with the sector (2010-2012)
Table 3.36 Financial ratios of ROCHE (HELLAS) S.A. and comparison with the sector (2010-2012)
Table 3.37 Financial ratios of MERCK SHARP & DOHME "MSD" S.A. and comparison with the sector (2010-2012)
Table 3.38 Financial ratios of ASTRAZENECA S.A. and comparison with the sector (2010-2012)
Table 3.39 Financial ratios of GENESIS PHARMA S.A. and comparison with the sector (2010-2012)
Table 3.40 Financial ratios of ABBOTT LABORATORIES (HELLAS) S.A. and comparison with the sector (2010-2012)
Table 3.41 Financial ratios of BAYER HELLAS A.G. and comparison with the sector (2010-2012)
Table 3.42 Financial ratios of PHARMASERVE LILLY S.A.C.I. and comparison with the sector (2010-2012)
Table 3.43 Financial ratios of BRISTOL - MYERS SQUIBB S.A. and comparison with the sector (2010-2012)
Table 3.44 Financial ratios of JANSSEN-CILAG PHARMACEUTICAL S.A.C.I. and comparison with the sector (2010-2012)
Table 3.45 Ranking of pharmaceutical importers based on gross profits (2011-2012)
Table 3.46 Ranking of pharmaceutical importers based on profit before income tax (2011-2012)
Table 3.47 Ranking of pharmaceutical importers based on EBITDA profits (2011-2012)
Table 3.48 Creditworthiness of Assessed Businesses (2013-2012)
Table 3.49 Creditworthiness of the manufacturing sector of Medicines-Cosmetics-Detergents (2013)
Table 3.50 Creditworthiness of the commercial sector of Medicines-Cosmetics-Detergents (2013)
Table 3.51 Trading conduct of assessed businesses (2013-2012)
Table 3.52 Trading Conduct in the Wider Sector of Pharmaceutical Companies (2013-2012)
App3.1 Breakdown of the advertising expenditure of pharmaceutical companies per medium (2006-2012)
App3.2 Breakdown of the advertising expenditure of pharmaceutical products per medium (2006-2012)
App3.3 Advertising expenditure of pharmaceutical companies per brand (2011-2012)
App3.4 Advertising expenditure of pharmaceutical products per brand (2011-2012)
App3.5 Formulae of financial ratios
Table 4.1 Value of sales of domestic medicines over time (2002-2012)
Table 4.2 Trade balance of medicines (2008-2012)
Table 4.3 Parallel Exports of Medicines
Table 4.4 The Domestic Market of Pharmaceutical Companies (2000-2012)
Table 4.5 Use of generic medicines by EOPYY (National Organization for the Provision of Healthcare Services)
Table 4.6 Public Debts to Pharmaceutical Companies (2011-2013)
Table 4.7 Market shares of pharmaceutical companies (2012)
Table 4.8 Concentration ratio in the market of pharmaceutical companies
App4.1 Description of Intrastat 8-digit Combined Nomenclature of External Trade Codes
App4.2 Imports of pharmaceutical products in value (2008-2012)
App4.3 Breakdown of imports by origin (2008-2012)
App4.4 Exports of pharmaceutical products in value (2008-2012)
App4.5 Breakdown of exports by destination (2008-2012)
Table 5.1 Overall Sales of Medicines globally (2008 - 2016)
Table 5.2 The pharmaceutical industry in Europe * (2008 - 2012)
Table 5.3 Information on the pharmaceutical industry per European country (2011)
Table 5.4 Research & Development Information about the Pharmaceutical Industry in Europe (2011)
App5.1 ΤBest selling medicines (2012)
App5.2 The top 10 pharmaceutical companies based on their total turnover (2012)
App5.2 The top 20 pharmaceutical companies based on their total turnover (2012)
App5.3 he top 10 pharmaceutical companies according to R&D (2012)
App5.4 Overall pharmaceutical expenditure as a share (%) in the gross domestic product in OECD member-states (1998-2011)
App5.5 Overall pharmaceutical expenditure as a share (%) in the overall health expenditure in OECD member-states (1998-2011)

GRAPHS

Graph 2.1 Pharmaceutical Expenditure over time (2005-2012)
Graph 3.1 Advertising expenditure of pharmaceutical products (2012)
Graph 3.2 Advertising expenditure of pharmaceutical companies (2012)
Graph 4.1 Value of sales of domestic medicines over time (2002-2012)
Graph 4.2 Imports of pharmaceutical products on value over time (2008-2012)
Graph 4.3 Exports of pharmaceutical products on value over time (2008-2012)
Graph 4.4 Trade balance and Balassa index of competitiveness in the sector of medicines (2008-2012)
Graph 4.5 The Domestic Market of Medicines Over Time (2000-2012)
Graph 4.6 Distribution of Public Debt to Pharmaceutical Companies (2011-2013)
Graph 5.1 Overall sales of Medicines globally over time (2008-2016)
Search
 

In-depth knowledge of the business sectors that you are interested in!

Customer Care
Tel: +30 210 7200 050
Email: customercare@icap.gr
 
Privacy Policy  |  Brochures  |  Site Map  |  Links
Designed & developed by EXUS | powered by eCentric Copyright © 2008-2017 ICAP GROUP. All rights reserved